Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NEU2 | Q9Y3R4 | 3/20 | 0.46 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.46 |
| ▸ | NEU3 | Q9UQ49 | 2/20 | 0.46 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.46 |
| ▸ | MAG | P20916 | 2/20 | 0.42 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.41 |
| ▸ | SELL | P14151 | 1/20 | 0.41 |
| ▸ | SELP | P16109 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13926096 | 1.00 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL15491955 | 1.00 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL1077555 | 0.89 | L3MBTL1 (0.44) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL20259100 | 0.88 | NANP (0.52) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL4184779 | 0.88 | NEU1 (0.48) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL4284548 | 0.86 | NANP (0.53) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL12391931 | 0.86 | NANP (0.53) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL123104 | 0.86 | NANP (0.53) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL13446667 | 0.86 | NANP (0.61) | NANPL3MBTL1NEU2NEU4NEU3 | |
| SCHEMBL23635227 | 0.85 | NANP (0.54) | NANPL3MBTL1NEU2NEU4NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| WO-2017068352-A1 | METHODS | THE ROYAL VETERINARY COLLEGE (GB) | 2017-04-27 | — | — | WO | claimed |
| US-9402910-B2 | Internally functionalized graphene substrates | NANOTECH BIOMACHINES, INC. (US) | 2016-08-02 | — | — | US | claimed |
| US-RE44302-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-06-18 | — | — | US | claimed |
| US-RE44017-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | YU RUEY J (US) | 2013-02-19 | — | — | US | claimed |
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| EP-2205217-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2010-07-14 | — | — | EP | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-RE41278-E1 | N-acetyl aldosamines and related N-acetyl compounds, and their topical use | TRISTRATA, INC. | 2010-04-27 | — | — | US | claimed |
| WO-2009042945-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (AN OHIO CORPORATION ) (US) | 2009-04-02 | — | — | WO | claimed |
| EP-1570840-A2 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050171194-A1 | Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions | YU RUEY J (US) | 2005-08-04 | — | — | US | claimed |
| US-6524593-B1 | Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails | TRISTRATA, INC. | 2003-02-25 | — | — | US | claimed |
| EP-1143925-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | Yu, Ruey J., Dr. (US) | 2001-10-17 | — | — | EP | claimed |
| US-6204029-B1 | MIXTURE OF ACTIVATED GLYCOSIDE DERIVITIVE, MUTANT GLYCOSYLTRANSFERASE, ACCEPTOR SUBSTRATE, AND NUCLEOTIDE PHOSPHATE OR ANALOG | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-03-20 | — | — | US | claimed |
| US-6159485-A | COSMETICS; SKIN DISORDERS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-12-12 | — | — | US | claimed |
| WO-2000040217-B1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-10-05 | — | — | WO | claimed |
| WO-2000040217-A1 | TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS | YUGENIC LIMITED PARTNERSHIP (US) | 2000-07-13 | — | — | WO | claimed |
| EP-0973932-A1 | IMPROVED SYNTHESIS OF OLIGOSACCHARIDES USING ACTIVATED GLYCOSIDE DERIVATIVES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-01-26 | — | — | EP | claimed |
| WO-1998046784-A1 | IMPROVED SYNTHESIS OF OLIGOSACCHARIDES USING ACTIVATED GLYCOSIDE DERIVATIVES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1998-10-22 | — | — | WO | claimed |